IL89500A - Human tissue plasminogen activator variants methods for their production and pharmaceutical compositions and preparations containing them - Google Patents

Human tissue plasminogen activator variants methods for their production and pharmaceutical compositions and preparations containing them

Info

Publication number
IL89500A
IL89500A IL8950089A IL8950089A IL89500A IL 89500 A IL89500 A IL 89500A IL 8950089 A IL8950089 A IL 8950089A IL 8950089 A IL8950089 A IL 8950089A IL 89500 A IL89500 A IL 89500A
Authority
IL
Israel
Prior art keywords
variant
des
native
site
amino acid
Prior art date
Application number
IL8950089A
Other languages
English (en)
Other versions
IL89500A0 (en
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22620139&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL89500(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL89500A0 publication Critical patent/IL89500A0/xx
Publication of IL89500A publication Critical patent/IL89500A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Artificial Filaments (AREA)
  • Inorganic Fibers (AREA)
IL8950089A 1988-03-21 1989-03-06 Human tissue plasminogen activator variants methods for their production and pharmaceutical compositions and preparations containing them IL89500A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/170,510 US5094953A (en) 1988-03-21 1988-03-21 Human tissue plasminogen activator variants

Publications (2)

Publication Number Publication Date
IL89500A0 IL89500A0 (en) 1989-09-10
IL89500A true IL89500A (en) 1998-09-24

Family

ID=22620139

Family Applications (1)

Application Number Title Priority Date Filing Date
IL8950089A IL89500A (en) 1988-03-21 1989-03-06 Human tissue plasminogen activator variants methods for their production and pharmaceutical compositions and preparations containing them

Country Status (13)

Country Link
US (4) US5094953A (da)
EP (1) EP0401303B2 (da)
JP (2) JP2605155B2 (da)
AT (1) ATE107960T1 (da)
AU (1) AU635892B2 (da)
CA (1) CA1341612C (da)
DE (1) DE68916532T3 (da)
DK (1) DK175776B1 (da)
ES (1) ES2018367A6 (da)
GR (1) GR1000387B (da)
IL (1) IL89500A (da)
NZ (1) NZ228401A (da)
WO (1) WO1989009266A1 (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI831484L (fi) * 1982-05-05 1983-11-06 Genentech Inc Plasminogen aktivator foer maenskovaevnad
KR840004781A (ko) * 1982-05-05 1984-10-24 월터 에이치·드레거 인체의 조직 플라스미노겐 활성화제
US5714372A (en) * 1985-04-22 1998-02-03 Genentech, Inc. Tissue plasminogen activator variants
HU217100B (hu) * 1987-10-29 1999-11-29 Yamanouchi Pharmaceutical Co. Ltd. Eljárás új polipeptidek előállítására
DE3923339A1 (de) * 1989-05-31 1990-12-06 Boehringer Mannheim Gmbh Gewebs-plasminogen-aktivator-derivat
US5242688A (en) * 1990-12-24 1993-09-07 Eli Lilly And Company Method of treating thromboembolic disorders by administration of diglycosylated t-pa variants
US5595736A (en) * 1991-04-22 1997-01-21 Eli Lilly And Company Compounds and methods for treatment of thromboembolic disorders
US5468505A (en) * 1992-02-28 1995-11-21 Board Of Regents, The University Of Texas System Local delivery of fibrinolysis enhancing agents
ATE226642T1 (de) * 1994-07-07 2002-11-15 Tno Modifizierte proenzyme als substrate für proteolische enzyme
US6136548A (en) * 1994-11-22 2000-10-24 Rutgers, The State University Of New Jersey Methods for identifying useful T-PA mutant derivatives for treatment of vascular hemorrhaging
US6461640B1 (en) 1995-12-08 2002-10-08 Board Of Regents, The University Of Texas System Local delivery of fibrinolysis enhancing agents
US20030113271A1 (en) * 1997-01-29 2003-06-19 University Technology Corporation Formulations for pulmonary delivery
CN101348789B (zh) * 1997-07-23 2016-08-17 罗切诊断学有限公司 通过同源重组在人细胞中生产人突变蛋白
US6136536A (en) * 1997-10-29 2000-10-24 Genetics Institute, Inc. Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins
US6283300B1 (en) 1998-08-21 2001-09-04 Joseph B. Bielagus Feed distribution for low velocity air density separation
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
JP3880036B2 (ja) * 2001-05-11 2007-02-14 全国酪農業協同組合連合会 タンパク質の濃縮方法
DE10153601A1 (de) * 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall
US20030149090A1 (en) * 2001-11-06 2003-08-07 Gehlsen Kurt R. Compositions for the treatment of infectious diseases
US20080057050A1 (en) * 2003-05-02 2008-03-06 Paion Deutschland Gmbh Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
DE10342518A1 (de) * 2003-09-12 2005-05-12 Paion Gmbh Plasminogen-Aktivatoren mit verringerter Lysin-Bindungskapazität
TWI482628B (zh) * 2007-10-18 2015-05-01 Lundbeck & Co As H 新穎之血栓溶解病患次群
US10220008B2 (en) 2013-08-14 2019-03-05 Stc.Unm Treatment and prevention of stroke and other neurological disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0199574B1 (en) * 1985-04-22 1991-10-23 Genentech, Inc. Human tissue plasminogen activator mutants, methods and intermediates therefor, and compositions using such mutants
ATE74379T1 (de) * 1985-12-23 1992-04-15 Chiron Corp Peptidplasminogenaktivatoren.
EP0293394B2 (en) * 1986-01-31 2003-10-29 Genetics Institute, LLC Novel thrombolytic proteins
EP0234051B1 (en) * 1986-02-17 1991-12-11 Stichting Centraal Laboratorium van de Bloedtransfusiedienst van het Nederlandse Rode Kruis Tissue-type plasminogen activator mutants; recombinant genetic information coding therefor and process for preparing said mutants; their use and pharmaceutical compositions
PT84588B (en) * 1986-04-02 1989-05-09 Beecham Group Plc Process for preparing a fibrinolytic enzyme
SE8702562L (sv) * 1987-06-18 1988-12-19 Kabigen Ab Nya fibrinolytiska enzymer
US4935237A (en) * 1988-03-21 1990-06-19 Genentech, Inc. Processes for the preparation of t-PA mutants
IL87276A (en) * 1987-08-03 1995-07-31 Fujisawa Pharmaceutical Co Analog of a tissue plasminogen activator containing the Pringle 2 and protease regions only, DNA encoding it, processes for its preparation, and pharmaceutical preparations containing it
EP0386240B1 (en) * 1987-10-29 1995-07-19 Yamanouchi Pharmaceutical Co. Ltd. Novel polypeptide compounds
DE3937589C2 (de) * 1989-11-10 2001-12-13 Laing Oliver Zirkulationsgerät mit Widerstandsheizung

Also Published As

Publication number Publication date
ES2018367A6 (es) 1991-04-01
GR1000387B (el) 1992-06-30
ATE107960T1 (de) 1994-07-15
JP2605155B2 (ja) 1997-04-30
EP0401303B1 (en) 1994-06-29
DE68916532T2 (de) 1995-01-12
US5366886A (en) 1994-11-22
US5094953A (en) 1992-03-10
US5770425A (en) 1998-06-23
DE68916532D1 (de) 1994-08-04
AU3414889A (en) 1989-10-16
DK227390A (da) 1990-09-20
US5314818A (en) 1994-05-24
CA1341612C (en) 2011-04-12
IL89500A0 (en) 1989-09-10
NZ228401A (en) 1991-09-25
EP0401303B2 (en) 1999-11-03
JPH03503363A (ja) 1991-08-01
GR890100164A (en) 1990-01-19
EP0401303A1 (en) 1990-12-12
AU635892B2 (en) 1993-04-08
DK175776B1 (da) 2005-02-14
DE68916532T3 (de) 2000-02-03
JPH09168387A (ja) 1997-06-30
DK227390D0 (da) 1990-09-20
WO1989009266A1 (en) 1989-10-05

Similar Documents

Publication Publication Date Title
CA1341612C (en) Human tissue plasminogen activator variants and processes
US5147643A (en) DNA sequences encoding human t-PA substituted at position 275 or at positions 275 and 277 and pharmaceutical compositions
EP0457758B1 (en) Tissue plasminogen activator having zymogenic or fibrin specific properties
US4935237A (en) Processes for the preparation of t-PA mutants
US5770426A (en) Tissue plasminogen activator having zymogenic or fibrin specific properties
US5073494A (en) Human tissue plasminogen activator substituted at position 275 or at positions 275 and 277
EP0424405B1 (en) Variants of plasminogen activators and processes for their production
US5338546A (en) Tissue plasminogen activator variants with decreased clearance
EP0365597B1 (en) Improved processes for the treatment of vascular disease
US5714372A (en) Tissue plasminogen activator variants
US5258180A (en) Tissue plasminogen activator having fibrin specific properties and deletion of amino acids 466-970, compositions and methods of treatment
US5037646A (en) Processes for the treatment of vascular disease
EP0517756B1 (en) Tissue plaminogen activator having fibrin specific properties
EP0542869B1 (en) Tissue plasminogen activator variants with decreased clearance
US5756093A (en) Tissue plasminogen activator variants
AU2079588A (en) Improved processes for the treatment of vascular disease

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed